A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: A children's oncology group experience

Clinical Cancer Research

Volumn 11, Issue 7, 2005, Pages 2644-2650

  Angiolillo, Anne L ^a,e   Davenport, Virginia ^b   Bonilla, Mary Ann ^b   Van De Ven, Carmella ^b   Ayello, Janet ^b   Militano, Olga ^b   Miller, Langdon L ^c   Krailo, Mark ^d   Reaman, Gregory ^d   Cairo, Mitchell S ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b Howard Hughes Medical Institute   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT THROMBOPOIETIN;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESMOPLASTIC SMALL ROUND CELL TUMOR; DRUG HALF LIFE; DRUG TOLERANCE; EWING SARCOMA; FIBROSARCOMA; GLIOMA; HEPATOBLASTOMA; HUMAN; HUMAN CELL; INFANT; LEUKOCYTE COUNT; MAXIMUM TOLERATED DOSE; MEGAKARYOCYTE; NEUROECTODERM TUMOR; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOLID TUMOR; STEM CELL; TOXICITY TESTING;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HUMANS; IFOSFAMIDE; MALE; MEGAKARYOCYTES; NEOPLASMS; RECOMBINANT PROTEINS; THROMBOPOIETIN;

EID: 20244376150     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1959     Document Type: Article

References (27)

1. Cairo MS, Shen V, Krailo MD, et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a Children's Cancer Group report. J Pediatr Hematol Oncol 2001;23:30-8.
2. Angiolillo A, Abu-Ghosh AM, Davenport V, Cairo MS. General aspects of thrombocytopenia, platelet transfusions and thrombopoietic growth factors. In: Kitchens C, Alving B, Kessler C, editors. Consultative hemostasis and thrombosis. Philadelphia: W.B. Saunders; 2002, p. 103-16.
3. Caen JP, Han ZC, Bellucci S, Alemany M. Regulation of megakaryocytopoiesis. Haemostasis 1999;29:27-40.
4. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369:533-8.
5. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 1994;91:11104-8.
6. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369:568-71.
7. Wendling F. Thrombopoietin: its role from early hematopoiesis to platelet production. Haematologica 1999;84:158-66.
8. Nurden P, Poujol C, Nurden AT. The evolution of megakaryocytes to platelets. Baillieres Clin Haematol 1997;10:1-27.
9. Prow D, Vadhan-Raj S. Thrombopoietin: biology and potential clinical applications. Oncology (Huntingt) 1998;12:1597-604, 1607-8; discussion 1611-4.
10. Chang M, Suen Y, Meng G, et al. Differential mechanisms in the regulation of endogenous levels thrombopoietin and interleukin-11 during thrombocytopenia: insight into the reg ulation of platelet production. Blood 1996;88:3345-62.
11. Kaushansky K. Thrombopoietin. N Engl J Med 1998;339:746-54.
12. Kaushansky K, Lin N, Grossmann A, Humes JM, Sprugel KH, Broudy VC. Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol 1996;24:265-9.
13. Grossmann A, Lenox J, Deisher TA, et al. Synergistic effects of thrombopoietin and granulocyte colony-stimulating factor on neutrophil recovery in myelosuppressed mice. Blood 1996;88:3363-70.
14. Akahori H, Shibuya K, Obuchi M, et al. Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. Br J Haematol 1996;94:722-8.
15. van de Ven C, Fernandez GW, Herbst T, Knoppel A, Kulczyk ST, Cairo MS. The haemopoietic effects of thrombopoietin administered post-myelosuppressive carboplatin therapy compared to either pre- and post- or pre-chemotherapy. Br J Haematol 1998;102:775-82.
16. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997;126:673-81.
17. Vadhan-Raj S, Patel S, Broxmeyer HE, et al. Phase I-II investigation of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with Adriamycin (A) and ifosfamide (I). Blood 1996;88:448a.
18. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000;132:364-8.
19. Vadhan-Raj S, Patel S, Bueso-Ramos C, et al. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol 2003;21:3158-67.
20. Turnbull B. The empirical distribution function from arbitrarily grouped, censored and truncated data. J R Stat Soc Ser B 1976;:290-5.
21. Bracho F, Krailo MO, Shen V, et al. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities. Clin Cancer Res 2001;7:58-67.
22. Ishibashi T, Kimura H, Shikama Y, et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 1989;74:1241-4.
23. Herodin F, Mestries JC, Janodet D, et al. Recombinant glycosylated human interleukin-6 accelerates peripheral blood platelet count recovery in radiation-induced bone marrow depression in baboons. Blood 1992;80:688-95.
24. Wolff SN, Herzig R, Lynch J, et al. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study. Bone Marrow Transplant 2001;27:261-8.
25. Murray LJ, Leuns KM, Estrada MF, et al. Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis. Exp Hematol 1998;26:207-16.
26. Vadhan-Raj S, Broxmeyer HE, Andreef M, et al. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-2 in cancer patients with normal hematopoiesis: a phase I study. Blood 1995;86:2098-105.
27. Cairo MS, Krailo MD, Weinthal JA, et al. A phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group. Cancer 1998;83:1449-60.